Are Vyzulta (latanoprostene bunod) and Zolymbus (netarsudil) in the same drug class?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, Vyzulta and Rhopressa (netarsudil) are NOT in the same drug class

Vyzulta (latanoprostene bunod) is classified as a prostaglandin analog, while Rhopressa/netarsudil (the active ingredient in Zolymbus) is classified as a Rho kinase (ROCK) inhibitor 1, 2.

Key Distinctions Between the Two Medications

Vyzulta (Latanoprostene Bunod)

  • Drug Class: Prostaglandin analog with nitric oxide-donating properties 2
  • Mechanism: Rapidly metabolized to latanoprost (a prostaglandin F2α analog) and butanediol mononitrate (nitric oxide donor), enhancing aqueous outflow through both uveoscleral and trabecular meshwork pathways 1, 2
  • IOP Reduction: Comparable to other prostaglandin analogs
  • Common Side Effects: Conjunctival hyperemia, increased iris pigmentation (typical of prostaglandin class)

Netarsudil (in Zolymbus/Rhopressa)

  • Drug Class: Rho kinase (ROCK) inhibitor 1
  • Mechanism: Increases trabecular outflow, decreases episcleral venous pressure, and decreases aqueous production 1
  • IOP Reduction: 10-20% 1
  • Common Side Effects: Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage, keratitis 1

Clinical Implications

While both medications can cause conjunctival hyperemia, they work through fundamentally different mechanisms and belong to distinct pharmacologic classes. Netarsudil represents a novel class of glaucoma medications that directly targets the trabecular meshwork outflow pathway, whereas Vyzulta is essentially an enhanced prostaglandin analog that combines traditional prostaglandin effects with nitric oxide donation 3, 4.

Important Caveat

The fact that these are different drug classes means they can potentially be used together or sequentially without redundancy in mechanism of action. However, netarsudil is also available in a fixed-dose combination with latanoprost (Rocklatan), which would overlap mechanistically with Vyzulta's prostaglandin component 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.